Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Down 44.4% in November

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 9,500 shares, a drop of 44.4% from the October 31st total of 17,100 shares. Based on an average daily volume of 13,800 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Lisata Therapeutics in a report on Thursday, November 21st.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned 0.21% of Lisata Therapeutics worth $60,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Stock Performance

NASDAQ:LSTA traded down $0.02 during midday trading on Thursday, reaching $2.82. 6,757 shares of the stock traded hands, compared to its average volume of 13,881. The stock has a market capitalization of $23.66 million, a PE ratio of -1.12 and a beta of 1.22. Lisata Therapeutics has a 12-month low of $2.05 and a 12-month high of $3.83. The business has a 50-day moving average of $2.92 and a two-hundred day moving average of $3.09.

Lisata Therapeutics (NASDAQ:LSTA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same period in the previous year, the business posted ($0.65) EPS. Research analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current year.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.